Takeda recruits GE to help discover new liver treatments

Damian Garde The growing scourge of liver disease in the developed world has spurred a frenzied race among drug developers to ferret out new therapies, and Takeda, new to the field, ...

Top teaching hospitals urge Congress to ‘review’ Genentech distribution change

Carly Helfand Roche's Genentech unit is facing more pushback over distribution-channel changes for its three best-selling cancer treatments. Leaders from top U.S. teaching hospitals ...

Place your bets: Biotechs hustle along new drugs for blockbuster liver diseases

John Carroll Late last week investors wound up using Intercept Pharmaceuticals as a punching bag after new data on its NASH drug for fatty liver disease raised some troubling questions ...

Judge’s ‘serious questions’ about Ackman trading in Allergan may fire SEC into action

Carly Helfand Valeant partner and leading Allergan shareholder Bill Ackman may have won the right to vote his shares at a Dec. 18 special meeting, at which he hopes to upturn Allergan's ...

Battered ArQule shares bump up on badly needed positive data for tivantinib

John Carroll ArQule's badly battered shares managed a quick surge this morning on news that the biotech's lead drug tivantinib scored a positive outcome in a Phase II metastatic ...

Need more on ex-Sanofi CEO Viehbacher’s sudden exit?

Carly Helfand If you haven't yet read enough about ex-Sanofi CEO Chris Viehbacher's departure, check out Bloomberg's latest. FiercePharma News

Japan unveils sunshine data of its own, raising eyebrows after Diovan scandal

Tracy Staton Just as the dust is settling after the big rollout of doctor-payment data in the U.S., a new round has made its debut–in Japan. According to The Japan News, the country's ...

Amgen takes another stride in frenzied race toward the PCSK9 finish line

John Carroll Amgen now has a deadline in place for an FDA decision on its cholesterol-lowering drug evolocumab. The Big Biotech put out the word Monday morning that the FDA has accepted ...

UCB joins pharma’s slimdown craze, unloads U.S. generic drug business for $1.53B

Emily Wasserman Amid the pharma's slimdown craze, Belgium's UCB is getting in on the action by selling its U.S. generic drug unit for $ 1.53 billion. FiercePharma News

Rockwell clears an FDA hurdle with its dialysis drug

Damian Garde A group of FDA advisers voted in favor of approving Rockwell Medical's iron-replacement treatment for dialysis patients, setting aside concerns about the drug's ...

AcelRx CEO Richard King steps down

Alok Saboo FierceBiotech News

Fresenius kills Russian partnership as political tensions escalate

Eric Palmer Building political tensions between Russia and the West are making it increasingly difficult for drugmakers in the region, prompting Germany's Fresenius to dump a partnership ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS